Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

NCT00963235 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

331

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
Pneumococcal Infections

Interventions

BIOLOGICAL: 13-valent pneumococcal conjugate vaccine
PROCEDURE: Blood draw

Sponsor

Pfizer